ALSO NOTED: Pliva to buy generics division; Avian flu virus spreading fast; and much more...

> Fresh from wrapping a deal to sell its R&D arm to GlaxoSmithKline, Croatia's Pliva has inked a deal to buy the Spanish division of Novartis' generics division for 21.5 million euros. Report

> The avian flu virus has now penetrated Germany and Austria with a suspected case in Denmark. Report

> Abbott has selected two additional cancer targets from Celera Genomics. Celera now has seven antigens in the research pipeline with partners. Release

> Pro-Pharmaceuticals of Newton, MA is raising $10 million through a private placement. Report

> The FDA has accepted Merck's NDA for Januvia, an experimental therapy for Type 2 diabetes. Release

> Ranbaxy has reportedly made a bid for German generic manufacturer Betapharm. Report

> Emisphere Technologies of Tarrytown, NY has hit a second milestone in its collaboration with Roche on bone-related diseases. Release

> Progenics Pharmaceuticals announced positive top-line results from the second pivotal phase 3 clinical trial of methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced medical illness. Release

> Insurers are looking at big savings as generics replace a host of blockbusters this year. Report

> The FDA plans to investigate the deaths of four women who took the abortion pill RU-486. Report

> Eli Lilly and Boehringer Ingelheim are restructuring their deal for Yentreve. Release

And Finally… A psychiatrist doubts that new addiction drugs will replace therapists anytime soon. Article

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.

Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test.